parallel randomized trial

NCT02490176

Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure

Design

Randomized: 52
Start year: 2014
Treatment: 1 weeks, follow-up 13.04 weeks
Countries: China (1 sites)
Sponsor: Binzhou Medical University Hospital (non industry)
Eligibility: heart failure with ejection fraction below 50 percent; eGFR 60 or more

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Placebo Placebo	stable beta blocker, ACE inhibitor or ARB and diuretics; lifestyle: not reported	26	26
A2	Liraglutide 1.8 mg subcutaneous once daily Liraglutide	stable beta blocker, ACE inhibitor or ARB and diuretics; lifestyle: not reported	26	26

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Placebo A1	Liraglutide 1.8 mg subcutaneous once daily A2
age	mean (years)	58.7	59.1
age	sd (years)	11.4	11.8
bmi	mean (kg/m2)	24.8	25.3
bmi	sd (kg/m2)	3.8	3.4
egfr	mean (mL/min/1.73 m2)	83.5	81.4
egfr	sd (mL/min/1.73 m2)	20.3	19.5
established cvd	n	20	21
established cvd	percent	77	81
hba1c	mean (percent)	5.3	5.4
hba1c	sd (percent)	0.4	0.6
lvef	mean (percent)	42.1	42.2
lvef	sd (percent)	7.3	7.1
other male	n	19	20
other male	percent	73	77
sbp	mean (mmHg)	115	118
sbp	sd (mmHg)	13	14

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Three point MACE (2 lines; O21)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				5 / 26	not stated; randomized; R0020399:Table 6
	A2	events				3 / 26	not stated; randomized; R0020399:Table 6

Hospitalization for heart failure (2 lines; O23)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 26	not stated; randomized; R0020399:Table 6
	A2	events				1 / 26	not stated; randomized; R0020399:Table 6

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				1 / 26	not stated; randomized; R0020399:Results
	A2	events				3 / 26	not stated; randomized; R0020399:Results